Eli Lilly Strengthens GLP-1 Leadership With New Foundayo Trial Results
INDIANAPOLIS, May 12, 2026 Eli Lilly and Company has reported positive results from two major late-phase obesity trials showing...
metabolic disease
Advertisement
Novo Nordisk Expands Wegovy Leadership at ECO 2026
BAGSVAERD, Denmark, May 12, 2026 Novo Nordisk announced new clinical findings at the 2026 European Congress on Obesity (ECO...
Novo Nordisk Reports 28% Weight Loss With Higher-Dose Wegovy
Bagsværd, Denmark, May 12, 2026 Novo Nordisk presented new analyses from its pivotal STEP UP clinical trial at the...
Boehringer Survodutide Shows 16.6% Weight Loss in Phase III
INGELHEIM, GERMANY, April 28, 2026 Boehringer Ingelheim has announced positive Phase III results for its investigational dual agonist survodutide,...
Anaxiom AVOS Device Shows Safe Early Obesity Results
LAGUNA HILLS, Calif., April 2026 Anaxiom Corporation has announced encouraging early clinical results from its first-in-human study of the...
Advertisements
FDA Approves Lilly Foundayo Oral GLP-1 Weight Loss Drug
INDIANAPOLIS, USA — April 1, 2026 In a landmark advancement in obesity treatment and metabolic disease management, Eli Lilly...
Sun Pharma Launches Semaglutide in India Market
MUMBAI, INDIA, March 21, 2026 Sun Pharmaceutical Industries Limited has announced the launch of its semaglutide injection under the...
Innovent Doses First Patient in Phase 3 IBI128 Trial
San Francisco, USA / Suzhou, China | March 22, 2026 Innovent Biologics has announced that the first participant has...
Novo Nordisk Wegovy HD Approved with 20% Weight Loss
BAGSVÆRD, Denmark, March 19, 2026 Novo Nordisk A/S announced that the U.S. Food and Drug Administration (FDA) has approved...
Hanmi Expands GLP-1 Obesity Drug Reach Through Mexico Deal
SEOUL, SOUTH KOREA | January 27, 2026 — Hanmi Pharmaceutical, the core operating company of Hanmi Science, announced a...
Advertisement
